VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa-Reference-Cited by-同舟云学术

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa

Published:2020-02-21 Issue:3 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Hamrick Jodie C.¹,Docquier Jean-Denis²^ORCID,Uehara Tsuyoshi¹,Myers Cullen L.¹,Six David A.¹,Chatwin Cassandra L.¹,John Kaitlyn J.¹,Vernacchio Salvador F.¹,Cusick Susan M.¹,Trout Robert E. L.¹,Pozzi Cecilia³^ORCID,De Luca Filomena²^ORCID,Benvenuti Manuela³^ORCID,Mangani Stefano³^ORCID,Liu Bin¹,Jackson Randy W.¹,Moeck Greg¹,Xerri Luigi¹,Burns Christopher J.¹,Pevear Daniel C.¹,Daigle Denis M.¹^ORCID

Affiliation:

1. Venatorx Pharmaceuticals Incorporated, Malvern, Pennsylvania, USA

2. Department of Medical Biotechnology, University of Siena, Siena, Italy

3. Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy

Abstract

As shifts in the epidemiology of β-lactamase-mediated resistance continue, carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are the most urgent threats.

Funder

HHS | National Institutes of Health

Wellcome Trust

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01963-19

Reference58 articles.

1. Game Changers: New β-Lactamase Inhibitor Combinations Targeting Antibiotic Resistance in Gram-Negative Bacteria

2. A β-lactamase inhibitor revival provides new hope for old antibiotics

3. A review of global initiatives to fight antibiotic resistance and recent antibiotics׳ discovery

4. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections

5. CDC. 2019. Antibiotic resistance threats in the United States 2019. CDC, U.S. Department of Health and Human Services, Atlanta, GA. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacodynamics of taniborbactam in combination with cefepime studied in an in vitro model of infection;International Journal of Antimicrobial Agents;2024-10

2. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime;Antimicrobial Agents and Chemotherapy;2024-09-04

3. Cefepime–Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination;Drugs;2024-08-30

4. Approachable Synthetic Methodologies for Second-Generation β-Lactamase Inhibitors: A Review;Pharmaceuticals;2024-08-23

5. New antibiotics in clinical pipeline for treating infections caused by metallo-β-lactamases producing Gram-negative bacteria;Current Opinion in Infectious Diseases;2024-08-01